MYGN Stock Might Gain on The Lancet Study Backing Precise MRD

Myriad Genetics (MYGN) announced the publication in The Lancet Oncology of a study validating its Precise MRD test for oligometastatic clear-cell renal cell carcinoma (ccRCC), demonstrating its ability to identify patients who can delay or avoid systemic therapies while maintaining strong survival rates (e.g., 87% at three years for ctDNA negative). This significant clinical advancement, expected to bolster MYGN's oncology business in the rapidly growing $4.5 billion MRD market, saw the company's shares decline 2.7% following the news.

Analysis

Myriad Genetics (MYGN) has secured significant clinical validation for its Precise MRD test with a study published in The Lancet Oncology, demonstrating its efficacy in managing oligometastatic clear-cell renal cell carcinoma. The test successfully identified patients who could delay systemic therapy, with ctDNA-negative individuals remaining on metastasis-directed therapy for a median of 54 months versus 27 months for ctDNA-positive patients, while maintaining high survival rates of 87% at three years. This development supports MYGN's strategy to expand its oncology business within the minimal residual disease (MRD) testing market, which is projected to reach $4.5 billion by 2030 at a 10.1% CAGR. However, there is a notable disconnect between this positive clinical news and market sentiment. The company's stock declined 2.7% following the announcement and has fallen 75.5% over the past year, drastically underperforming its industry. This investor skepticism persists despite the company consistently surpassing earnings estimates over the last four quarters with an average surprise of 210%, suggesting the market requires more than clinical data to reverse the stock's trajectory.

Key Decisions for Investors

• Investors should closely monitor for evidence of commercial adoption and revenue contribution from the Precise MRD test, as the market's negative reaction suggests skepticism about the company's ability to translate clinical wins into financial results.
• Given the stock's 75.5% year-over-year decline against a backdrop of positive earnings surprises and pipeline progress, MYGN presents a high-risk, potential turnaround scenario for investors with a high tolerance for volatility.
• It is crucial to watch for a shift in market sentiment and a clear catalyst, such as upgraded revenue guidance or significant commercial partnerships, before committing new capital, as the current trend remains decidedly negative despite recent positive developments.